degrasyn and Neoplasms

degrasyn has been researched along with Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for degrasyn and Neoplasms

ArticleYear
USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.
    Cancer medicine, 2019, Volume: 8, Issue:15

    BRCA1, a multifunctional protein with an important role in DNA double-strand break repair by homologous recombination (HR), is subjected to ubiquitin-dependent degradation. To date, several E3 ubiquitin ligases have been identified to govern BRCA1 stability, but the deubiquitinase that counteracts its turnover remains undefined. In this study, we report that the ubiquitin-specific protease 9X (USP9X) is a bona fide deubiquitinase for BRCA1 in human cancer cells. Reciprocal immunoprecipitation assays demonstrated that USP9X interacted with BRCA1. Depletion of USP9X by short interfering RNAs or inhibition of USP9X by the small-molecular inhibitor WP1130 significantly reduced BRCA1 protein abundance, without affecting its mRNA levels. In contrast, overexpression of wild-type USP9X, but not its deubiquitinase activity-defective mutant (C1566S), resulted in an upregulation of BRCA1 protein levels. Moreover, USP9X depletion reduced the half-life of BRCA1, accompanied by an increase in its ubiquitination. HR assays showed that knockdown of USP9X significantly reduced HR efficiency, which was partially rescued by reintroduction of BRCA1 into USP9X-depleted cells. In support of these findings, USP9X knockdown significantly enhanced sensitivity to PARP inhibitor Olaparib and methyl methanesulfonate (MMS). Collectively, these results establish USP9X as a deubiquitinase for BRCA1 and reveal a previously unrecognized role of USP9X in the regulation of HR repair and the sensitivity of cancer cells to DNA-damaging agents.

    Topics: Antineoplastic Agents; BRCA1 Protein; Cell Line, Tumor; Cyanoacrylates; Drug Resistance, Neoplasm; Gene Knockout Techniques; HEK293 Cells; HeLa Cells; Humans; MCF-7 Cells; Methyl Methanesulfonate; Neoplasms; Phthalazines; Piperazines; Pyridines; Ubiquitin Thiolesterase; Ubiquitination

2019
Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.
    Cancer research, 2010, Nov-15, Volume: 70, Issue:22

    Recent evidence suggests that several deubiquitinases (DUB) are overexpressed or activated in tumor cells and many contribute to the transformed phenotype. Agents with DUB inhibitory activity may therefore have therapeutic value. In this study, we describe the mechanism of action of WP1130, a small molecule derived from a compound with Janus-activated kinase 2 (JAK2) kinase inhibitory activity. WP1130 induces rapid accumulation of polyubiquitinated (K48/K63-linked) proteins into juxtanuclear aggresomes, without affecting 20S proteasome activity. WP1130 acts as a partly selective DUB inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37, which are known to regulate survival protein stability and 26S proteasome function. WP1130-mediated inhibition of tumor-activated DUBs results in downregulation of antiapoptotic and upregulation of proapoptotic proteins, such as MCL-1 and p53. Our results show that chemical modification of a previously described JAK2 inhibitor results in the unexpected discovery of a novel DUB inhibitor with a unique antitumor mechanism.

    Topics: Apoptosis; Blotting, Western; Carboxypeptidases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyanoacrylates; Endopeptidases; HEK293 Cells; Humans; Inclusion Bodies; Microscopy, Confocal; Neoplasms; Nitriles; Proteasome Endopeptidase Complex; Pyridines; RNA Interference; Tumor Suppressor Protein p53; Ubiquitin; Ubiquitin Thiolesterase

2010